| Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters CW le Roux, SJB Aylwin, RL Batterham, CM Borg, F Coyle, V Prasad, ... Annals of surgery 243 (1), 108-114, 2006 | 1236 | 2006 |
| Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours JK Ramage, AHG Davies, J Ardill, N Bax, M Caplin, A Grossman, ... Gut 54 (suppl 4), iv1-iv16, 2005 | 704 | 2005 |
| Attenuated peptide YY release in obese subjects is associated with reduced satiety CW Le Roux, RL Batterham, SJB Aylwin, M Patterson, CM Borg, ... Endocrinology 147 (1), 3-8, 2006 | 665 | 2006 |
| Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance LA Lotta, P Gulati, FR Day, F Payne, H Ongen, M Van De Bunt, ... Nature genetics 49 (1), 17-26, 2017 | 528 | 2017 |
| Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD CJ Ricketts, JR Forman, E Rattenberry, N Bradshaw, F Lalloo, L Izatt, ... Human mutation 31 (1), 41-51, 2010 | 408 | 2010 |
| Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety CM Borg, CW Le Roux, MA Ghatei, SR Bloom, AG Patel, SJB Aylwin Journal of British Surgery 93 (2), 210-215, 2006 | 408 | 2006 |
| Germline CDKN1B/p27Kip1 Mutation in Multiple Endocrine Neoplasia M Georgitsi, A Raitila, A Karhu, RB van der Luijt, CM Aalfs, T Sane, ... The Journal of Clinical Endocrinology & Metabolism 92 (8), 3321-3325, 2007 | 324 | 2007 |
| Tumour risks and genotype–phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD KA Andrews, DB Ascher, DEV Pires, DR Barnes, L Vialard, RT Casey, ... Journal of medical genetics 55 (6), 384-394, 2018 | 217 | 2018 |
| Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation CW le Roux, C Borg, K Wallis, RP Vincent, M Bueter, R Goodlad, ... Annals of surgery 252 (1), 50-56, 2010 | 214 | 2010 |
| Effectiveness of metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients E Daniel, S Aylwin, O Mustafa, S Ball, A Munir, K Boelaert, V Chortis, ... The Journal of Clinical Endocrinology & Metabolism 100 (11), 4146-4154, 2015 | 208 | 2015 |
| The impact of obesity surgery and the paradox of control: A qualitative study J Ogden, C Clementi, S Aylwin Psychology & health 21 (2), 273-293, 2006 | 199 | 2006 |
| Visceral adiposity is closely correlated with neck circumference and represents a significant indicator of insulin resistance in WHO grade III obesity L Yang, YP Samarasinghe, P Kane, SA Amiel, SJB Aylwin Clinical endocrinology 73 (2), 197-200, 2010 | 132 | 2010 |
| Expanding the Spectrum of Mutations in GH1 and GHRHR: Genetic Screening in a Large Cohort of Patients with Congenital Isolated Growth Hormone Deficiency KS Alatzoglou, JP Turton, D Kelberman, PE Clayton, A Mehta, ... The Journal of Clinical Endocrinology & Metabolism 94 (9), 3191-3199, 2009 | 126 | 2009 |
| Phaeochromocytoma crisis BC Whitelaw, JK Prague, OG Mustafa, KM Schulte, PA Hopkins, JA Gilbert, ... Clinical endocrinology 80 (1), 13-22, 2014 | 123 | 2014 |
| Exploring the impact of obesity surgery on patients' health status: a quantitative and qualitative study J Ogden, C Clementi, S Aylwin, A Patel Obesity surgery 15 (2), 266-272, 2005 | 121 | 2005 |
| Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR) α1 and TRα2: clinical, biochemical, and genetic analyses of three related patients C Moran, M Agostini, WE Visser, E Schoenmakers, N Schoenmakers, ... The lancet Diabetes & endocrinology 2 (8), 619-626, 2014 | 120 | 2014 |
| Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors M Korbonits, RA Jacobs, SJB Aylwin, JM Burrin, PLM Dahia, JP Monson, ... The Journal of Clinical Endocrinology & Metabolism 83 (10), 3624-3630, 1998 | 117 | 1998 |
| Temozolomide in the management of dopamine agonist–resistant prolactinomas BC Whitelaw, D Dworakowska, NW Thomas, S Barazi, P Riordan‐Eva, ... Clinical endocrinology 76 (6), 877-886, 2012 | 115 | 2012 |
| Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor SJB Aylwin, I Bodi, R Beaney Pituitary 19, 544-546, 2016 | 110 | 2016 |
| Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial CE Higham, AB Atkinson, S Aylwin, M Bidlingmaier, WM Drake, A Lewis, ... The Journal of Clinical Endocrinology & Metabolism 97 (4), 1187-1193, 2012 | 108 | 2012 |
